Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange

Journal of Clinical Gastroenterology

Volumn 45, Issue 6, 2011, Pages 551-555

  Mao, Wei Lin ^a   Chen, Yu ^a,b   Chen, Yue Mei ^b   Li, Lan Juan ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

acute on chronic liver failure (AoCLF); cytokines; plasma exchange (PE)

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE BLOOD LEVEL; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL;

CYTOKINES; END STAGE LIVER DISEASE; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PLASMA EXCHANGE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958787800     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181faefa3     Document Type: Article

References (25)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogesis. Ann Rev Immunol. 1995;13:29-60.
2. Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology. 1997;112:193-199. (Pubitemid 27009002)
3. Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74-80. (Pubitemid 24049800)
4. Minoru A, Tetsuya I, Akihiko O, et al. Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatol Res. 2006;34:214-221.
5. Yumoto E, Higashi T, Nouso K, et al. Serum gammainterferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol. 2002;17:285-294. (Pubitemid 34534101)
6. Bozkaya H, Bozdayi M, Türkyilmaz R, et al. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterol. 2000;47:1675-1679.
7. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver disease. Gastroenterology. 1992;103:264-274.
8. Nagaki M, Iwai H, Naiki T, et al. High levels of serum interleukin-10 and tumor necrosis factor-a are associated with fatality in fulminant hepatitis. J Infect Dis. 2000;182:1103-1108.
9. Odeh M, Sabo E, Srugo I, et al. Serum levels of tumor necrosis factor-a correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int. 2004;24:110-116. (Pubitemid 38584996)
10. Yoshiba M, Inoue K, Sekiyama K, et al. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs. 1996;20:1169-1172. (Pubitemid 26371022)
11. Matsubara S. Combination of plasma exchange and continuous hemofiltration as temporary metabolic support for patients with acute liver failure. Artif Organs. 1994;18:363-366. (Pubitemid 24167248)
12. Kondrup J, Almdal T, Vilstrup H, et al. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs. 1992;15:669-676. (Pubitemid 23035827)
13. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002;20:252-261. (Pubitemid 34195668)
14. Huo TI, Wu JC, Lin HC, et al. Evaluation of the increase in model for end-stage liver disease (DMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J. Hepatol. 2005;42:826-832.
15. Huo TI, Lin HC, Wu JC, et al. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl. 2006;12:65-71.
16. The group of the artificial liver of Society of Infectious Diseases and Parasitic Diseases, CMA. Operating guide for artificial liver support system. Zhonghua Gan Zang Bing Za Zhi. 2002;10:329-333. (In Chinese).
17. Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol. 2001;8:961-965.
18. Simpson KJ. Cytokines, for better or worse? Eur J Gastrenterol Hepatol. 1999;11:957-966.
19. Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol. 2000;15:480-488. (Pubitemid 30327048)
20. Nagaki M, Hughes RD, Lau JY, et al. Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding. Int J Artif Organs. 1991;14:43-50.
21. Nagaki M, Hughes RD, Keane HM, et al. In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circ Shock. 1992;38:182-188.
22. Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, et al. In vivo induction of interleukin-1 during hemodialysis. Kidney Int. 1989;35:1212-1218.
23. Bingel M, Lonnemann G, Koch KM, et al. Plasma interleukin-1 activity during hemodialysis: the influence of dialysis membranes. Nephron. 1988;50:273-276.
24. Ghysen J, Plaen JF, Strihou CY. The effect of membrane characteristics on tumor necrosis factor kinetics during haemodialysis. Nephrol Dial Transplant. 1990;5:270-274. (Pubitemid 20204469)
25. Janbon B, Vuillez JP, Carpentier F, et al. Removal of circulating tumor necrosis factor: its role in septic shock treatment. Ann Med Interne. 1992;143:13-16. (Pubitemid 23043736)